Replies to post #148105 on Biotech Values

[Summer2762]

I havent heard of this portfolio review before. All I could find about it was the following quote in the latest CC.

We are currently undergoing a very detailed review of every project that's part of the R&D portfolio. DiaPep is part of that, and we will be reporting on the outcome of all of this during our Investor Day in December.

Do you have more info about this?

Anyway, I dont believe they would cut it just before the SYNERGY's interim analysis. They would look really stupid if the interim crosses the boundary. If they have any intention to do so, they would wait few more months for the interim and then announce it.

I agree, if they do, that will be a major opportunity to invest in OGXI.